ES2662444T3 - Derivado de piridina - Google Patents
Derivado de piridina Download PDFInfo
- Publication number
- ES2662444T3 ES2662444T3 ES13854714T ES13854714T ES2662444T3 ES 2662444 T3 ES2662444 T3 ES 2662444T3 ES 13854714 T ES13854714 T ES 13854714T ES 13854714 T ES13854714 T ES 13854714T ES 2662444 T3 ES2662444 T3 ES 2662444T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- carbon atoms
- optionally substituted
- ring
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 27
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
Un derivado de piridina representado por la siguiente fórmula (I) o una sal farmacéuticamente aceptable del mismo, o un solvato del mismo: **(Ver fórmula)** en donde: A representa un enlace sencillo, un átomo de oxígeno, un átomo de azufre, NH o CH2; R1 representa un átomo de nitrógeno o CH; uno de X1 a X5 representa un átomo de nitrógeno y los cuatro restantes representan CR2; cada R2 representa independientemente un átomo de hidrógeno, un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alquenilo que tiene de 2 a 6 átomos de carbono, un grupo alquinilo que tiene de 2 a 6 átomos de carbono, un átomo de halógeno, un grupo trifluorometilo, un grupo difluorometilo, un grupo ciano, un grupo alquilcarbonilo que tiene de 2 a 7 átomos de carbono, un grupo alquilsulfonilo que tiene de 1 a 6 átomos de carbono, un grupo nitro, un grupo amino, un grupo dialquilamino que tiene de 1 a 6 átomos de carbono que pueden formar opcionalmente un anillo, un grupo formilo, un grupo hidroxilo, un grupo alcoxi que tiene de 1 a 6 átomos de carbono (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo, un grupo fenilo, un grupo ciclohexilo y un átomo de halógeno), un grupo alquiltio que tiene de 1 a 6 átomos de carbono, un grupo fenilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), o un grupo fenoxi (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), con la condición de que cuando dos de CR2 son adyacentes, los dos de R2 pueden estar unidos opcionalmente para formar un anillo; R3 representa un átomo de hidrógeno, un grupo alquilo que tiene de 1 a 6 átomos de carbono (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo, un grupo amino, un grupo dialquilamino que tiene de 1 a 6 átomos de carbono que pueden formar opcionalmente un anillo, un anillo de imidazol, un anillo de pirazol, un anillo de pirrolidina, un anillo de piperidina, un anillo de morfolina y un anillo de piperazina (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono y un grupo alquilsulfonilo que tiene de 1 a 6 átomos de carbono)), un grupo alquenilo que tiene de 2 a 6 átomos de carbono, un grupo alquinilo que tiene de 2 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo y un átomo de halógeno), un grupo alquilcarbonilo que tiene de 2 a 7 átomos de carbono, un grupo alquiltio que tiene de 1 a 6 átomos de carbono, un grupo alquilsulfinilo que tiene de 1 a 6 átomos de carbono, un átomo de halógeno, un grupo trifluorometilo, un grupo difluorometilo, un grupo ciano, un grupo fenilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), un grupo piridilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), un grupo fenoxi (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), un grupo carboxilo o -CO2R5; R4 representa un grupo carboxilo, un grupo tetrazolilo, -CONHSO2R5, -CO2R5, o cualquiera de los siguientes sustituyentes: ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012250661 | 2012-11-14 | ||
| PCT/JP2013/080706 WO2014077285A1 (ja) | 2012-11-14 | 2013-11-13 | ピリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2662444T3 true ES2662444T3 (es) | 2018-04-06 |
Family
ID=50731196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13854714T Active ES2662444T3 (es) | 2012-11-14 | 2013-11-13 | Derivado de piridina |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9637469B2 (es) |
| EP (2) | EP3339302A1 (es) |
| JP (2) | JP5774238B2 (es) |
| KR (1) | KR20150082194A (es) |
| CN (2) | CN107721931A (es) |
| AR (1) | AR093468A1 (es) |
| AU (2) | AU2013345894B2 (es) |
| BR (1) | BR112015010977A2 (es) |
| CA (1) | CA2891408A1 (es) |
| CL (1) | CL2015001279A1 (es) |
| CY (1) | CY1120127T1 (es) |
| DK (1) | DK2944633T3 (es) |
| ES (1) | ES2662444T3 (es) |
| HR (1) | HRP20180451T1 (es) |
| HU (1) | HUE037736T2 (es) |
| IL (2) | IL238539A (es) |
| LT (1) | LT2944633T (es) |
| MA (1) | MA38078B1 (es) |
| ME (1) | ME03016B (es) |
| MX (1) | MX2015003672A (es) |
| NO (1) | NO2944633T3 (es) |
| NZ (1) | NZ708031A (es) |
| PE (1) | PE20150974A1 (es) |
| PH (1) | PH12015501037A1 (es) |
| PL (1) | PL2944633T3 (es) |
| PT (1) | PT2944633T (es) |
| RS (1) | RS57090B1 (es) |
| RU (1) | RU2640588C2 (es) |
| SA (1) | SA515360431B1 (es) |
| SG (2) | SG10201705852PA (es) |
| SI (1) | SI2944633T1 (es) |
| SM (1) | SMT201800322T1 (es) |
| TW (1) | TWI666205B (es) |
| UA (1) | UA117359C2 (es) |
| WO (1) | WO2014077285A1 (es) |
| ZA (1) | ZA201503322B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015260300A1 (en) | 2014-05-13 | 2016-12-22 | Teijin Pharma Limited | Pyrazine derivative |
| AR100404A1 (es) * | 2014-05-13 | 2016-10-05 | Teijin Pharma Ltd | Polimorfos cristalinos de un derivado de piridina y método para producirlos |
| EP3429355B1 (de) | 2016-03-15 | 2020-02-05 | Bayer CropScience AG | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| EP3466946B1 (en) * | 2016-05-23 | 2023-08-30 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| UY37556A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| AU2018208422B2 (en) | 2017-01-10 | 2021-11-11 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
| CN109251184B (zh) * | 2017-07-13 | 2021-06-15 | 浙江海正药业股份有限公司 | 一种2-三氟甲基苯磺酰胺类衍生物的医药用途 |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| KR20220098170A (ko) | 2019-11-07 | 2022-07-11 | 바이엘 악티엔게젤샤프트 | 동물 해충 방제를 위한 치환된 술포닐 아미드 |
| US20230247994A1 (en) | 2020-07-02 | 2023-08-10 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN114315729B (zh) * | 2021-12-09 | 2024-01-26 | 大连理工大学 | 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用 |
| WO2025026738A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1599032A (en) | 1977-03-04 | 1981-09-30 | May & Baker Ltd | Imidazole derivatives having herbicidal activity |
| JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| PL149675B1 (pl) | 1986-03-10 | 1990-03-31 | Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5 | |
| US4770689A (en) * | 1986-03-10 | 1988-09-13 | Janssen Pharmaceutica N.V. | Herbicidal imidazole-5-carboxylic acid derivatives |
| DD260928A5 (de) | 1986-06-06 | 1988-10-12 | Ciba-Geigy Ag,Ch | Verfahren zur herstellung neuer aralkylimidizolderivate |
| MY100938A (en) | 1986-06-06 | 1991-05-31 | Ciba Geigy Ag | Arylkylimidazole derivatives. |
| JPH08119936A (ja) * | 1994-10-18 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 複素環式誘導体 |
| IT1295405B1 (it) | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
| EP1310485A4 (en) | 2000-07-28 | 2005-07-20 | Sumitomo Pharma | Pyrrole derivatives |
| NZ522150A (en) | 2001-02-22 | 2006-03-31 | Teijin Ltd | Benzo[b]thiophene derivatives and processes for preparing the same |
| AU2003902828A0 (en) * | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| BRPI0819847B1 (pt) * | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| US8450500B2 (en) * | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| CN102186832B (zh) * | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
| JP2010202575A (ja) | 2009-03-03 | 2010-09-16 | Takeda Chem Ind Ltd | 複素環化合物 |
| WO2011005969A2 (en) * | 2009-07-10 | 2011-01-13 | The General Hospital Corporation | Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| CN102035579B (zh) * | 2009-09-28 | 2014-09-03 | 夏普株式会社 | 信息反馈方法和用户设备 |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| JP5485811B2 (ja) * | 2010-06-23 | 2014-05-07 | 株式会社ジャパンディスプレイ | 双方向シフトレジスタ、及びこれを用いた画像表示装置 |
| MA34797B1 (fr) | 2010-08-11 | 2014-01-02 | Millennium Pharm Inc | Hétéroaryles et leurs utilisations |
-
2013
- 2013-11-13 PE PE2015000616A patent/PE20150974A1/es not_active Application Discontinuation
- 2013-11-13 EP EP18152142.8A patent/EP3339302A1/en not_active Withdrawn
- 2013-11-13 TW TW102141292A patent/TWI666205B/zh not_active IP Right Cessation
- 2013-11-13 DK DK13854714.6T patent/DK2944633T3/en active
- 2013-11-13 SI SI201330943T patent/SI2944633T1/en unknown
- 2013-11-13 SM SM20180322T patent/SMT201800322T1/it unknown
- 2013-11-13 KR KR1020157008457A patent/KR20150082194A/ko not_active Withdrawn
- 2013-11-13 WO PCT/JP2013/080706 patent/WO2014077285A1/ja not_active Ceased
- 2013-11-13 UA UAA201505767A patent/UA117359C2/uk unknown
- 2013-11-13 CN CN201710933918.5A patent/CN107721931A/zh active Pending
- 2013-11-13 LT LTEP13854714.6T patent/LT2944633T/lt unknown
- 2013-11-13 HU HUE13854714A patent/HUE037736T2/hu unknown
- 2013-11-13 CN CN201380059519.0A patent/CN104797570B/zh not_active Expired - Fee Related
- 2013-11-13 NO NO13854714A patent/NO2944633T3/no unknown
- 2013-11-13 AR ARP130104172A patent/AR093468A1/es unknown
- 2013-11-13 AU AU2013345894A patent/AU2013345894B2/en not_active Ceased
- 2013-11-13 US US14/441,074 patent/US9637469B2/en not_active Expired - Fee Related
- 2013-11-13 SG SG10201705852PA patent/SG10201705852PA/en unknown
- 2013-11-13 PT PT138547146T patent/PT2944633T/pt unknown
- 2013-11-13 RU RU2015122698A patent/RU2640588C2/ru active
- 2013-11-13 PL PL13854714T patent/PL2944633T3/pl unknown
- 2013-11-13 ME MEP-2018-91A patent/ME03016B/me unknown
- 2013-11-13 BR BR112015010977A patent/BR112015010977A2/pt not_active Application Discontinuation
- 2013-11-13 JP JP2014547007A patent/JP5774238B2/ja not_active Expired - Fee Related
- 2013-11-13 SG SG11201503770VA patent/SG11201503770VA/en unknown
- 2013-11-13 ES ES13854714T patent/ES2662444T3/es active Active
- 2013-11-13 HR HRP20180451TT patent/HRP20180451T1/hr unknown
- 2013-11-13 RS RS20180390A patent/RS57090B1/sr unknown
- 2013-11-13 MX MX2015003672A patent/MX2015003672A/es unknown
- 2013-11-13 CA CA2891408A patent/CA2891408A1/en not_active Abandoned
- 2013-11-13 NZ NZ708031A patent/NZ708031A/en not_active IP Right Cessation
- 2013-11-13 MA MA38078A patent/MA38078B1/fr unknown
- 2013-11-13 EP EP13854714.6A patent/EP2944633B1/en active Active
-
2015
- 2015-01-16 JP JP2015007229A patent/JP6293068B2/ja not_active Expired - Fee Related
- 2015-04-30 IL IL238539A patent/IL238539A/en not_active IP Right Cessation
- 2015-05-08 PH PH12015501037A patent/PH12015501037A1/en unknown
- 2015-05-12 CL CL2015001279A patent/CL2015001279A1/es unknown
- 2015-05-13 ZA ZA2015/03322A patent/ZA201503322B/en unknown
- 2015-05-13 SA SA515360431A patent/SA515360431B1/ar unknown
- 2015-12-17 IL IL243193A patent/IL243193A0/en unknown
-
2017
- 2017-03-22 US US15/466,088 patent/US20170190694A1/en not_active Abandoned
- 2017-07-07 AU AU2017204665A patent/AU2017204665A1/en not_active Abandoned
-
2018
- 2018-04-10 CY CY20181100389T patent/CY1120127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR093468A1 (es) | Derivados de piridina | |
| JO3425B1 (ar) | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| EA201291414A1 (ru) | Имидазопиридиновые производные, способ их получения и терапевтическое использование | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| UA109775C2 (xx) | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| UA113643C2 (xx) | N-цикліламіди як нематоциди | |
| NZ710052A (en) | Novel pyrazol derivatives | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| PH12016502358A1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR096152A1 (es) | Derivados de purina | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| MX2015013365A (es) | Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag). | |
| EA201590069A1 (ru) | Пиримидиноновые производные в качестве антималярийных средств |